Pancreatic adenocarcinoma is the 4th leading cause of cancer in the USA. Its incidence is increasing both in France and in Europe, whereas all the other cancers are decreasing in Europe. Moreover, its seriousness is still high, with a mortality rate higher than the average incidence. The aim of PAPAFA study is to assess the prevalence of the pancreatic anomalies which can be revealed thanks to imaging, for patients having a 1st degree pancreatic adenocarcinoma familial history. This could allow detection of lesions which are less than 10 mm long, and improve the dark prognostic of this pathology.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
200
Pancreatic MRI in the 6 months following the first consultation
Clinique Convert
Bourg-en-Bresse, France
Infirmerie Protestante
Caluire-et-Cuire, France
Clinique du Val d'Ouest
Écully, France
Groupe Hospitalier Mutualiste des Eaux Claires
Grenoble, France
Centre des maladies du foie et de l'appareil digestif
Irigny, France
Centre Hospitalier Saint Joseph Saint Luc
Lyon, France
Hôpital privé Jean Mermoz
Lyon, France
Clinique des Portes du Sud
Vénissieux, France
Hôpital de Villefranche
Villefranche-sur-Saône, France
Number of patients for whom the MRI and/or the echo endoscopy has shown a parenchymatous or ductal pancreatic anomaly
For every patients who will have a pancreatic MRI detecting an anomaly, the echo endoscopy will be done. A cytology of the lesion from the echo endoscopy will be done for the solid lesions and for the indetermined cystic lesions (that is to say, the lesions which don't meet the literature set criteria for serous kyst or intraductal papillary and mucinous tumor of the pancreas) ; which is usually done in health care.
Time frame: six months after the last inclusion
Number of patients for whom the MRI has brought to light a parenchymatous and/or ductal pancreatic anomaly
Time frame: six months after the last inclusion
Number of patients for whom the echo endoscopy has brought to light a parenchymatous and/or ductal pancreatic anomaly
Time frame: six months after the last inclusion
Height of the lesions
Time frame: six months after the last inclusion
Correlation between the data from the MRI and those from the echo endoscopy
Time frame: six months after the last inclusion
Localisation of the lesions
Time frame: six months after the last inclusion
Number of lesions
Time frame: six months after the last inclusion
Aspect of the lesion (solid and/or liquid)
Time frame: six months after the last inclusion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.